Matthew R Wilson
Overview
Explore the profile of Matthew R Wilson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter D, et al.
Br J Haematol
. 2024 Nov;
206(1):74-85.
PMID: 39506502
This good practice paper (GPP) is intended to support clinicians in assessing patient fitness for bleomycin and in management of bleomycin pulmonary toxicity (BPT) where it occurs. Bleomycin, originally developed...
2.
Wilson M, Cwynarski K, Eyre T, Smith J, Chaganti S, Fox C, et al.
Br J Haematol
. 2024 Aug;
205(6):2198-2205.
PMID: 39128894
This Good Practice Paper provides recommendations for the baseline investigation, risk stratification and use of prophylactic interventions for patients with large B-cell lymphoma at risk of central nervous system relapse....
3.
Henderson R, Wilson M
Br J Hosp Med (Lond)
. 2024 Jun;
85(6):1-9.
PMID: 38941979
Prompt diagnosis of lymphoma facilitates early treatment and improves outcomes for patients. For non-haemato-oncologists, it is important to have an understanding of how lymphoma can present and the initial work-up....
4.
OReilly M, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al.
Hemasphere
. 2024 Jun;
8(6):e87.
PMID: 38873532
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19 CAR T-cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA-2, brexu-cel demonstrated impressive responses in patients failing ≥2 lines, including...
5.
Wilson M, Kirkwood A, Doo N, Soussain C, Choquet S, Lees C, et al.
Am J Hematol
. 2023 Dec;
99(2):E46-E50.
PMID: 38037530
No abstract available.
6.
Bobillo S, Wilson M, Cwynarski K
Curr Opin Oncol
. 2023 Aug;
35(5):382-388.
PMID: 37551947
Purpose Of Review: Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) is an uncommon but devastating complication with an overall survival of less than 6 ...
7.
Wilson M, Haynes E, Parsons K, Hopkins D, Robertson E, Ferguson G, et al.
Br J Haematol
. 2023 Jun;
202(4):796-800.
PMID: 37357380
Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin,...
8.
Wilson M, Barrett A, Cheah C, Eyre T
Br J Haematol
. 2023 Feb;
201(2):185-198.
PMID: 36807902
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease...
9.
Wilson M, Bobillo S, Cwynarski K
Hematology Am Soc Hematol Educ Program
. 2022 Dec;
2022(1):138-145.
PMID: 36485105
The prevention of central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) continues to be one of the most contentious areas of lymphoma management. Outcomes for patients with...
10.
Eyre T, Savage K, Cheah C, El-Galaly T, Lewis K, McKay P, et al.
Lancet Oncol
. 2022 Sep;
23(9):e416-e426.
PMID: 36055310
CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have...